Initiate Phase 2 (IV) and Phase 1 (subcutaneous) clinical trials for ACU193
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Jan 2024
- Due
- 31 Dec 2024
- Delivered
- May 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Expect to initiate Phase 2 (IV) and Phase 1 (subcutaneous) studies in 2024”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 2 ALTITUDE-AD trial in May 2024 and conducted the Phase 1 subcutaneous trial in mid-2024, both meeting the 2024 deadline.
-
A Acumen Pharmaceuticals, Inc. 10-K filed 2025-03-27
“We also conducted a Phase 1 clinical trial investigating a subcutaneous dosing option of sabirnetug in mid-2024” ✓ confirmed on the page
-
A Acumen Pharmaceuticals, Inc. 10-K filed 2026-03-26
“We initiated our Phase 2 clinical trial, ALTITUDE-AD, in May 2024” ✓ confirmed on the page
Market reaction: the shares moved -3.5% against the S&P 500 over the three sessions around the disclosure (26 Mar 2025 to 31 Mar 2025). What this measures
Checked 25 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Initiate
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acumen Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-ABOS-000021 · Corrections policy